

Limited Use Label License

This Limited Use Label License specifically refers to plasmids listed in Schedule A (on the reverse of this page). The purchase of any these plasmids from Aldevron provides a license and conveys to the buyer limited, non-transferable rights to use the plasmids for "**GMP Production and Research Purposes**", as defined below, subject to the conditions set out in this License Agreement.

Your right to use the plasmids is subject to the following conditions and restrictions:

1. "**Research Purpose**" means any use for research purposes, other than "Commercial Purpose" and "GMP Production Purpose".
2. "**Commercial Purpose**" means the provision of commercial services to a third party for monetary gain, including but not limited to: (a) any use, directly or indirectly, in manufacturing and/or production, or quality control; or (b) any use to provide a service, information, or data for consideration. The use of any pALD Lenti plasmid for Commercial Purpose is strictly forbidden.
3. "**GMP Production Purpose**" means the use of plasmids listed in Schedule A for the manufacture of a therapeutic, diagnostic, prophylactic or other medicinal products intended for use in humans or non-human animals. If plasmids listed in Schedule A are used in the development of a molecule or any derivative of such molecule that is used in or administered to humans, then the production of such molecule shall be deemed to be GMP production.
4. You may not transfer the plasmids listed in Schedule A, to any third party for Commercial Purpose.
5. You may use the plasmids listed in Schedule A as a contract manufacturer to provide services to third parties provided your use is limited to performance of work for your direct customers for Research or GMP Production Purposes under the terms of this agreement.
6. The plasmids listed in Schedule A, or materials made through use of the these may be transferred by you to your legal affiliates or bonafide third party contractors performing paid work on your behalf, provided the use by such third-party contractors is limited to performance of work for you for Research or GMP Production Purposes under the terms of this agreement.
7. **Transgene Plasmid – Right to Modify but not Produce** – plasmids pALD-LentiEGFP-K (Q6974) and pALD-LentiEGFP-A (Q1365) may be modified through genetic DNA manipulation to yield new plasmid derivatives. pALD-LentiEGFP-K (Q6974) and pALD-LentiEGFP-A (Q1365) and derivatives may be transformed, amplified and grown using standard molecular approaches as required to establish the new construct. Further transformation, amplification, and growth must be done by Aldevron.
8. **Packaging Plasmids – No Right to Modify or Produce** – plasmids pALD-Rev-K (Q6972), pALD-VSV-G-K (Q6973), pALD-GagPol-K (Q6975), pALD-Rev-A (P6149), pALD-VSV-G-A (P6149), and pALD-GagPol-A (Q1550) may not be modified, re-transformed, grown, or expanded in any way.
9. Your right to use the plasmids listed in Schedule A will terminate immediately if you fail to comply with these terms and conditions. You shall, upon such termination of your rights, destroy the plasmids, and components and derivatives thereof in your control, and notify Oxford Genetics of such in writing.
10. You may use derivatives of the plasmid **pALD-LentiEGFP-K (Q6974) and pALD-LentiEGFP-A (Q1365)**, to support the filing of a patent application in any country in the world that contains claims directed to derivatives of pALD-LentiEGFP-K (Q6974) or pALD-LentiEGFP-A (Q1365).
11. You may not use the **Packaging Plasmids pALD-Rev-K (Q6972), pALD-VSV-G-K (Q6973), pALD-GagPol-K (Q6975), pALD-Rev-A (P6149), pALD-VSV-G-A (P6149), and pALD-GagPol-A (Q1550)** to support the filing of a patent application in any country in the world that contains claims directed to the **Packaging Plasmids pALD-Rev-K (Q6972), pALD-VSV-G-K (Q6973), pALD-GagPol-K (Q6975), pALD-Rev-A (P6149), pALD-VSV-G-A (P6149), and pALD-GagPol-A (Q1550)**.
12. You may not deposit the any plasmids listed in Schedule A, or any derivatives thereof, in any publicly accessible, institutional, or centralized repository, be it profit or non-profit based, without prior written approval of Oxford Genetics.
13. For further information contact legal@oxgene.com

Schedule A

| Research Grade | | GMP Source™ | |
|--------------------------------|---------------------------|-----------------------|---------------------------|
| Aldevron Item Number | Oxford Genetics Reference | Aldevron Item Number | Oxford Genetics Reference |
| 5028B pALD Lenti Mix (Kan) | Q6972, Q6973, Q6975 | 5042B pALD-Rev-K | Q6972 |
| 5028-1600 pALD Lenti Mix (Kan) | Q6972, Q6973, Q6975 | 5042-10 pALD-Rev-K | Q6972 |
| 5029B pALD Lenti Mix (Amp) | P6149, Q1550, P6189 | 5042-5 pALD-Rev-K | Q6972 |
| 5029-1600 pALD Lenti Mix (Amp) | P6149, Q1550, P6189 | 5043B pALD-Rev-A | P6149 |
| 5030B pALD-LentiEGFP-K | Q6974 | 5043-10 pALD-Rev-A | P6149 |
| 5030-10 pALD-LentiEGFP-K | Q6974 | 5043-5 pALD-Rev-A | P6149 |
| 5030-5 pALD-LentiEGFP-K | Q6974 | 5044B pALD-GagPol-K | Q6975 |
| 5031B pALD-LentiEGFP-A | Q1365 | 5044-10 pALD-GagPol-K | Q6975 |
| 5031-10 pALD-LentiEGFP-A | Q1365 | 5044-5 pALD-GagPol-K | Q6975 |
| 5031-5 pALD-LentiEGFP-A | Q1365 | 5045B pALD-GagPol-A | Q1550 |
| 5032B pALD-Rev-K | Q6972 | 5045-10 pALD-GagPol-A | Q1550 |
| 5032-10 pALD-Rev-K | Q6972 | 5045-5 pALD-GagPol-A | Q1550 |
| 5032-5 pALD-Rev-K | Q6972 | 5046B pALD-VSV-G-K | Q6973 |
| 5033B pALD-Rev-A | P6149 | 5046-10 pALD-VSV-G-K | Q6973 |
| 5033-10 pALD-Rev-A | P6149 | 5046-5 pALD-VSV-G-K | Q6973 |
| 5033-5 pALD-Rev-A | P6149 | 5047B pALD-VSV-G-A | P6189 |
| 5034B pALD-GagPol-K | Q6975 | 5047-10 pALD-VSV-G-A | P6189 |
| 5034-10 pALD-GagPol-K | Q6975 | 5047-5 pALD-VSV-G-A | P6189 |
| 5034-5 pALD-GagPol-K | Q6975 | | |
| 5035B pALD-GagPol-A | Q1550 | | |
| 5035-10 pALD-GagPol-A | Q1550 | | |
| 5035-5 pALD-GagPol-A | Q1550 | | |
| 5036B pALD-VSV-G-K | Q6973 | | |
| 5036-10 pALD-VSV-G-K | Q6973 | | |
| 5036-5 pALD-VSV-G-K | Q6973 | | |
| 5037B pALD-VSV-G-A | P6189 | | |
| 5037-10 pALD-VSV-G-A | P6189 | | |
| 5037-5 pALD-VSV-G-A | P6189 | | |